PortfoliosLab logoPortfoliosLab logo
NKTR vs. BRK-B
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

NKTR vs. BRK-B - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Nektar Therapeutics (NKTR) and Berkshire Hathaway Inc. (BRK-B). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, NKTR achieves a 57.73% return, which is significantly higher than BRK-B's -1.96% return. Over the past 10 years, NKTR has underperformed BRK-B with an annualized return of -11.08%, while BRK-B has yielded a comparatively higher 13.43% annualized return.


NKTR

1D
1.51%
1M
0.12%
YTD
57.73%
6M
50.00%
1Y
599.06%
3Y*
97.10%
5Y*
-23.55%
10Y*
-11.08%

BRK-B

1D
0.84%
1M
1.32%
YTD
-1.96%
6M
-1.54%
1Y
1.03%
3Y*
13.70%
5Y*
12.33%
10Y*
13.43%
*Multi-year figures are annualized to reflect compound growth (CAGR)

NKTR vs. BRK-B - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
NKTR
Nektar Therapeutics
57.73%203.08%64.60%-75.00%-83.27%-20.53%-21.26%-34.32%-44.96%386.72%
BRK-B
Berkshire Hathaway Inc.
-1.96%10.89%27.09%15.46%3.31%28.95%2.37%10.93%3.01%21.62%

Correlation

The correlation between NKTR and BRK-B is 0.02, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.02

Correlation (3Y)
Calculated over the trailing 3-year period

0.13

Correlation (5Y)
Calculated over the trailing 5-year period

0.17

Correlation (10Y)
Calculated over the trailing 10-year period

0.19

Correlation (All Time)
Calculated using the full available price history since May 9, 1996

0.21

The correlation between NKTR and BRK-B shifts across timeframes, from 0.02 (1 year) to 0.21 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

NKTR:

$1.65B

BRK-B:

$1.06T

EPS

NKTR:

-$8.64

BRK-B:

$33.62

PS Ratio

NKTR:

21.94

BRK-B:

2.83

PB Ratio

NKTR:

2.86

BRK-B:

1.46

Total Revenue (TTM)

NKTR:

$55.63M

BRK-B:

$375.39B

Gross Profit (TTM)

NKTR:

$44.58M

BRK-B:

$94.36B

EBITDA (TTM)

NKTR:

-$121.05M

BRK-B:

$71.92B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

NKTR vs. BRK-B — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NKTR
NKTR Risk / Return Rank: 9898
Overall Rank
NKTR Sharpe Ratio Rank: 9696
Sharpe Ratio Rank
NKTR Sortino Ratio Rank: 9999
Sortino Ratio Rank
NKTR Omega Ratio Rank: 9898
Omega Ratio Rank
NKTR Calmar Ratio Rank: 9898
Calmar Ratio Rank
NKTR Martin Ratio Rank: 9898
Martin Ratio Rank

BRK-B
BRK-B Risk / Return Rank: 4141
Overall Rank
BRK-B Sharpe Ratio Rank: 4545
Sharpe Ratio Rank
BRK-B Sortino Ratio Rank: 3636
Sortino Ratio Rank
BRK-B Omega Ratio Rank: 3636
Omega Ratio Rank
BRK-B Calmar Ratio Rank: 4545
Calmar Ratio Rank
BRK-B Martin Ratio Rank: 4545
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NKTR vs. BRK-B - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Nektar Therapeutics (NKTR) and Berkshire Hathaway Inc. (BRK-B). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


NKTRBRK-BDifference
Sharpe ratioReturn per unit of total volatility

+3.26

Sortino ratioReturn per unit of downside risk

+6.39

Omega ratioGain probability vs. loss probability

1.74

1.02

+0.72

Calmar ratioReturn relative to maximum drawdown

12.99

0.11

+12.88

Martin ratioReturn relative to average drawdown

27.75

0.23

+27.52

NKTR vs. BRK-B - Sharpe Ratio Comparison

The current NKTR Sharpe Ratio is 3.33, which is higher than the BRK-B Sharpe Ratio of 0.07. The chart below compares the historical Sharpe Ratios of NKTR and BRK-B, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

NKTR vs. BRK-B - Drawdown Comparison

The maximum NKTR drawdown since its inception was -99.61%, which is greater than BRK-B's maximum drawdown of -53.86%. Use the drawdown chart below to compare losses from any high point for NKTR and BRK-B.


Loading charts...

Drawdown Indicators


NKTRBRK-BDifference

Max Drawdown

Largest peak-to-trough decline

-99.61%

-53.86%

-45.75%

Max Drawdown (1Y)

Largest decline over 1 year

-46.54%

-9.42%

-37.12%

Max Drawdown (3Y)

Largest decline over 3 years

-73.20%

-14.95%

-58.25%

Max Drawdown (5Y)

Largest decline over 5 years

-97.76%

-26.58%

-71.18%

Max Drawdown (10Y)

Largest decline over 10 years

-99.61%

-29.57%

-70.04%

Current Drawdown

Current decline from peak

-95.90%

-8.71%

-87.19%

Average Drawdown

Average peak-to-trough decline

-68.35%

-11.07%

-57.28%

Ulcer Index

Depth and duration of drawdowns from previous peaks

21.74%

4.57%

+17.17%

Volatility

NKTR vs. BRK-B - Volatility Comparison

Nektar Therapeutics (NKTR) has a higher volatility of 14.19% compared to Berkshire Hathaway Inc. (BRK-B) at 3.75%. This indicates that NKTR's price experiences larger fluctuations and is considered to be riskier than BRK-B based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


NKTRBRK-BDifference

Volatility (1M)

Calculated over the trailing 1-month period

14.19%

3.75%

+10.44%

Volatility (6M)

Calculated over the trailing 6-month period

60.56%

10.63%

+49.93%

Volatility (1Y)

Calculated over the trailing 1-year period

181.62%

14.39%

+167.23%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

121.88%

17.10%

+104.78%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

97.17%

19.39%

+77.78%

Dividends

NKTR vs. BRK-B - Dividend Comparison

Neither NKTR nor BRK-B has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

NKTR vs. BRK-B - Financials Comparison

This section allows you to compare key financial metrics between Nektar Therapeutics and Berkshire Hathaway Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00B40.00B60.00B80.00B100.00B20222023202420252026
10.86M
93.68B
(NKTR) Total Revenue
(BRK-B) Total Revenue
Values in USD except per share items

Frequently Asked Questions


NKTR and BRK-B have a correlation of 0.02, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

NKTR has higher volatility (14.19%) compared to BRK-B (3.75%). In terms of maximum drawdown, NKTR dropped -99.61% vs BRK-B's -53.86%.

NKTR currently has the higher Sharpe Ratio (3.33 vs 0.07), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for NKTR and BRK-B

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer